Brief: Almirall Announces Positive, Top-Line Results From Phase 3 Adorable-1 Trial
16/03/2026 11:11
March 16 (Reuters) - Almirall SA ALM.MC: ANNOUNCES POSITIVE, TOP-LINE RESULTS FROM PHASE 3 ADORABLE-1 TRIAL LEBRIKIZUMAB DELIVERED SIGNIFICANT SKIN CLEARANCE AND IMPROVED DISEASE SEVERITY IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ADORABLE-1 MET CO-PRIMARY EFFICACY ENDPOINTS, WITH 63% OF PAEDIATRIC PATIENTS ACHIEVING MEANINGFUL SKIN IMPROVEMENT (EASI-75) AND 44% REACHING CLEAR OR ALMOST CLEAR SKIN (IGA 0,1) AT WEEK 16 Source text Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24